IN8bio Inc. Common Stock (INAB)
Stock · NASDAQ · Health Care
$1.11as of 10/16/2026
Price chart
Active signals
INAB Signal Track Record
How signals performed across all stocks →What INAB's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 26 | -2.6% | 50% | July 28, 2026 |
| Volume Spike | 24 | -11.3% | 29% | October 1, 2026 |
| Bollinger Band Breakout | 20 | -15.1% | 20% | September 28, 2026 |
| 200-Day Moving Average TouchActive now | 12 | -12.9% | 25% | May 29, 2026 |
| Any 20-session window (baseline) | -7.8% | 35% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About INAB
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate th…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 18
- Website
- www.in8bio.com
Fundamentals
- 1-day range
- $1.14$1.23
- Market cap
- $9.55M
- P/E (trailing)
- —
- P/E (forward)
- -1.26
- EPS (trailing)
- $-2.05
- Dividend yield
- —
- Beta
- 0.24
- Avg. volume
- 56.5K
Forecasts
3 analyst ratings
IN8bio Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- INABIN8bio Inc. Common Stock$1.11▼ 6.33%Market cap $9.55MP/E —$0.88$2.73
- CRISCuris Inc. Common Stock$0.41▼ 19.61%Market cap $8.59MP/E —$0.5733$33.6
- BCDABioCardia Inc. Common Stock$0.92▼ 2.13%Market cap $10.80MP/E —$0.75$1.8
- SNTISenti Biosciences Holdings Inc. Common Stock$0.225▼ 14.12%Market cap $11.18MP/E —$0.2399$2.88
- INTSIntensity Therapeutics Inc. Common stock$3.35▼ 0.89%Market cap $11.49MP/E —$3.1$43.5
- CELZCreative Medical Technology Holdings Inc. Common Stock$0.741▼ 9.39%Market cap $7.58MP/E —$0.62$6.25
- AIMAIM ImmunoTech Inc. Common Stock$0.17▲ 0.00%Market cap $7.51MP/E —$0.1605$2.79
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| INAB IN8bio Inc. Common Stock | $9.55M | — | $1.11 | ▼ 6.33% | $0.88$2.73 |
| CRIS Curis Inc. Common Stock | $8.59M | — | $0.41 | ▼ 19.61% | $0.5733$33.6 |
| BCDA BioCardia Inc. Common Stock | $10.80M | — | $0.92 | ▼ 2.13% | $0.75$1.8 |
| SNTI Senti Biosciences Holdings Inc. Common Stock | $11.18M | — | $0.225 | ▼ 14.12% | $0.2399$2.88 |
| INTS Intensity Therapeutics Inc. Common stock | $11.49M | — | $3.35 | ▼ 0.89% | $3.1$43.5 |
| CELZ Creative Medical Technology Holdings Inc. Common Stock | $7.58M | — | $0.741 | ▼ 9.39% | $0.62$6.25 |
| AIM AIM ImmunoTech Inc. Common Stock | $7.51M | — | $0.17 | ▲ 0.00% | $0.1605$2.79 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/6/2026
- 12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga · 9/24/2026
- IN8bio to Present at Sidoti Small-Cap Virtual ConferenceYahoo · 9/22/2026
Insider Activity
Insider Actions →- Emily Fairbairn · May 27, 2026 · Gift724.6K
- Graff Jeremy R. · May 9, 2026 · Grant22.0K
- Rochlin Kate · May 9, 2026 · Grant60.0K
- McCall Patrick · May 9, 2026 · Grant56.3K
- Greenwood Luba · May 9, 2026 · Grant22.0K
- Epperly Corinne · May 9, 2026 · Grant22.0K
- Ho William Tai-Wei · May 9, 2026 · Grant154.5K
- Lamb Lawrence · May 9, 2026 · Grant54.0K
- Emily Fairbairn · May 9, 2026 · Grant22.0K
- Brandt Peter C. · May 9, 2026 · Grant22.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 3.66M
- Total value held
- $5.42M
- Institutional holders
- 18
- Unknown944.3K
- Unknown914.5K
- Unknown724.6K
- Unknown663.4K
- Unknown167.8K
- Unknown86.2K
- Unknown43.6K
- Unknown33.3K
- Unknown24.0K
- Unknown23.8K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
IN8bio Reports Inducement Grant Under Nasdaq Rule
IN8bio disclosed an inducement grant in compliance with Nasdaq Listing Rule 5635(c)(4). This filing is a standard corporate governance procedure used to attract or retain key employees. The stock is currently trading near its 52-week high, with technical indicators showing recent support rejection.
IN8bio Reports Inducement Grant Under Nasdaq Rule. IN8bio disclosed an inducement grant in compliance with Nasdaq Listing Rule 5635(c)(4). This filing is a standard corporate governance procedure used to attract or retain key employees. The stock is currently trading near its 52-week high, with technical indicators showing recent support rejection.